Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing

Abstract excerpt

The MET gene is located on chromosome 7q21-31 and encodes for a protein tyrosine kinase. The incidence of MET fusions in NSCLC are rare [1]. Currently, a total of six MET fusion partner genes have been reported in NSCLC, including KIF5B−, STARD3NL−, HLA-DRB1−, UBE2H−, SLC1A2−, and PTPRZ1− [1–4]. Previous cases have shown the efficacy of crizotinib in NSCLC patients with MET fusions [1, 3]. Herein we report a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer therapeutics and mechanisms
• Share to Cholangiocarcinoma and Gallbladder Cancer Studies
• Share to Lung Cancer Treatments and Mutations